Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ‘trans-signal’ in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.

Introduction

Interleukin-6 (IL-6) is a cytokine that has been known by a variety of names, reflecting its diverse actions on various cell types. Early studies identified this molecule as a T-cell derived stimulus to IgG production by B lymphoblastoid cell lines [1] and a B-cell growth factor [2]. Following the independent cloning of the IL-6 gene in 1986, it became known as B-cell stimulatory factor-2 (BSF-2) or B-cell differentiation factor, reflecting its ability to promote the differentiation of B cells into immunoglobulin-producing cells [3]. Interleukin-6 was also named interferon β2 (IFNβ2), due to its interferon-like antiviral activity [4]. Identity of IL-6 with hepatocyte-stimulating factor was reported shortly thereafter, indicating its ability to promote the synthesis of acute phase proteins by hepatocytes [5]. Finally, the myeloid blood cell differentiation-inducing protein type 2A (MGI-2A) proved to be identical to IL-6, reflecting the myeloid differentiating properties of this cytokine [6]. To achieve a unified nomenclature for this pleiotropic cytokine, it was finally named as IL-6 in 1988 [7].

It is now appreciated that IL-6 is a multi-functional cytokine that plays important roles in inflammation [8,9], immune response [10], haematopoiesis [11,12], lipid metabolism [13], vascular disease [14], mitochondrial activity [15], insulin resistance [16], and in both the neuropsychological [17] and neuroendocrine systems [18]. Moreover, it is now established that IL-6 is involved in several disease types, including autoimmune disease and cancer [1923].

Structure of IL-6 and its receptor

Interleukin-6 is a member of the haematopoietic cytokine family and is a 21–28 kDa glycosylated protein composed of four long antiparallel α helices (A, B, C, and D) [2426]. These helices are arranged in an up-up-down-down topology, forming three distinct epitopes which act as receptor-binding sites, namely sites I, II, and III [2732] (Figure 1). Site I is formed by residues at the C-terminal of helix D and AB loop and acts as a binding site for the non-signalling IL-6 receptor subunit, IL-6Rα [31,33,34]. Site II is located on helix A and helix C and is formed by the binary interaction of IL-6 and IL-6Rα with the signal transducer glycoprotein (gp)130 between domain 2 and domain 3 [30,34]. Site III is composed of residues found in the N-terminal of the AB loop and residues at the C-terminal of helix D [32,35,36]. This site interacts with the Ig-like domain (IGD), also known as domain 1 (D1), of gp130 (Glycoprotein 130) to form a competent signalling complex [33,34,3739].

IL-6R complex.

Figure 1.
IL-6R complex.

Schematic side/top views of the IL-6/IL-6R/gp130 complex show that IL-6 (red) binds to both IL-6R (black) and gp130 (blue) forming a signalling complex. IL-6 binds to domains D2 and D3 of the IL-6R through binding site I, and via sites II and III to the cytokine-binding domain D3 and the Ig-like domain D1 of gp130, respectively.

Figure 1.
IL-6R complex.

Schematic side/top views of the IL-6/IL-6R/gp130 complex show that IL-6 (red) binds to both IL-6R (black) and gp130 (blue) forming a signalling complex. IL-6 binds to domains D2 and D3 of the IL-6R through binding site I, and via sites II and III to the cytokine-binding domain D3 and the Ig-like domain D1 of gp130, respectively.

Interleukin-6 receptor α is an 80 kDa glycoprotein, also named gp80 and CD126, that is expressed only on restricted cell lineages [40]. This low-affinity receptor binds to IL-6 via residues within domain 2 and domain 3, resulting in the recruitment of the signal-transducing β-subunit gp130 to form a high-affinity IL-6R complex that is capable of signal transduction [40,41]. It is noteworthy that both the transmembrane domain and the cytoplasmic portion of IL-6R are not signalling competent, meaning that they can be removed without affecting IL-6 signalling [40]. gp130, also called CD130 and IL-6Rβ, is a 130 kDa glycoprotein that is ubiquitously expressed in all tissues and acts as a signal transducer for the IL-6-type cytokine family, which includes interleukin-11 (IL-11), oncostatin M (OSM), leukaemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), and ciliary neurotrophic factor (CNTF) [42]. The gp130 subunit is unable to engage either IL-6 or IL-6Rα alone as it only associates with the complex IL-6/IL-6R through (i) the formed binary site II, which binds to the two cytokine-binding domains (CBDs) D2 and D3 of gp130 and (ii) site III to D1 of gp130 [34,43]. Functional studies have suggested that the high-affinity IL-6R complex is a hexamer, consisting of two distinct copies of IL-6, IL-6R, and gp130 [32,34]; however, a tetramer model containing one molecule of IL-6, IL-6R and two molecules of gp130 has also been proposed [44,45].

Signal transduction activated by IL-6

Once the IL-6/IL-6R/gp130 complex has assembled, multiple downstream signalling events take place that allow IL-6 to exert its pleiotropic actions, including differentiation, proliferation, survival, and apoptosis. Signals activated by the receptor complex are mediated via the Janus tyrosine kinase (JAK)–STAT (signal transducers and activators of transcription), Ras/Raf/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), or Src/YAP pathways [4652]. Upon gp130 dimerisation, JAK kinases interact through their FERM domain (Band-4.1, ezrin, radixin, moesin; also known as the N-terminal JAK-homology domain) with the membrane proximal box1 and box2 regions of gp130 [53,54]. This leads to JAK kinase activation and subsequent gp130 phosphorylation (Figure 2). Docking sites are created as a result that allows the recruitment and phosphorylation of STAT3, to a lesser extent STAT1 and to the least extent STAT5. Cells that lack JAK1 have impaired IL-6 signal transduction, indicating the crucial role of this particular kinase in IL-6 function [55]. On the other hand, both JAK2 and Tyk2 (tyrosine kinase-2) appear to be dispensable in this regard [56]. In turn, STAT3 can enhance the expression of IL-6, creating a feed-forward loop that has been implicated in cancer progression [57].

The activation of JAK–STAT pathway via IL-6.

Figure 2.
The activation of JAK–STAT pathway via IL-6.

Upon IL-6R complex formation, two gp130 molecules dimerise, resulting in JAK activation, and subsequent phosphorylation of the cytoplasmic tyrosine residues of gp130. STAT3 becomes phosphorylated after binding the phosphorylated residues of gp130 and disassociates from the receptor, translocating to the nucleus as homodimers that drive gene expression.

Figure 2.
The activation of JAK–STAT pathway via IL-6.

Upon IL-6R complex formation, two gp130 molecules dimerise, resulting in JAK activation, and subsequent phosphorylation of the cytoplasmic tyrosine residues of gp130. STAT3 becomes phosphorylated after binding the phosphorylated residues of gp130 and disassociates from the receptor, translocating to the nucleus as homodimers that drive gene expression.

JAK–STAT signalling via gp130 is strictly regulated through the involvement of various suppressors and inhibitors such as protein inhibitor of activated STAT (PIAS) proteins, suppressor of cytokine signalling proteins (SOCS), and cytokine-inducible SH2 (src homology-2) domain-containing protein (CISH), all of which function as feedback inhibitors that ultimately restrict IL-6 signalling [58]. Illustrating this, mice that express a mutant gp130 lacking the ability to bind SOCS3 exhibit sustained activation of STAT1 and STAT3, resulting in the development of chronic inflammatory disease and cancer [59,60]. Further discussion of IL-6-mediated signal transduction is provided in a recent review [61].

Interleukin-6 receptor isoforms influence whether classic- or trans-signalling occurs

Interleukin-6 receptor exists not only as a membrane-bound receptor (mbIL-6R), but also as a soluble isoform (sIL-6R) [62]. Soluble IL-6R is produced either via proteolysis of the ectodomain of the mbIL-6Rα by metalloproteinases including ADAM17 and ADAM10, or less frequently (1–20%) by alternative splicing of IL-6R mRNA [6365]. Both forms of IL-6R bind IL-6 with similar affinity [66]. Importantly, however, the complex formed between IL-6 and sIL-6R can initiate autocrine or paracrine IL-6 signalling in any cell type that expresses gp130, through a process known as IL-6 trans-signalling (Figure 3) [67]. On the other hand, when IL-6 binds to a cell that expresses mbIL-6R, classic signalling ensues. Broadly speaking, trans-signalling promotes pro-inflammatory processes, while classic signalling is anti-inflammatory [68,69]. In both cases, gp130 homodimerisation is responsible for signalling. Recently, a putative third mode of IL-6 signalling was described by Heink et al. [70], referred to as ‘IL-6 trans-presentation’. In this mode of signalling, dendritic-associated membrane-anchored IL-6R binds to IL-6 and this complex engages gp130 on a recipient T cell. It should be noted that this system has been demonstrated using murine cells but remains untested in the human system.

Classic- and trans-signalling by IL-6.

Figure 3.
Classic- and trans-signalling by IL-6.

(A) Interleukin-6-mediated formation of an mbIL-6R/gp130 complex elicits classic signalling. (B) In contrast, when soluble forms of IL-6R are released following ADAM17-mediated cleavage or variant mRNA splicing, trans-signalling may occur in cell types that express gp130 alone.

Figure 3.
Classic- and trans-signalling by IL-6.

(A) Interleukin-6-mediated formation of an mbIL-6R/gp130 complex elicits classic signalling. (B) In contrast, when soluble forms of IL-6R are released following ADAM17-mediated cleavage or variant mRNA splicing, trans-signalling may occur in cell types that express gp130 alone.

To add complexity, gp130 also exists as many soluble isoforms. Soluble gp130 functions as a selective antagonist of IL-6 trans-signalling [71], binding exclusively to IL-6/sIL-6R to promote the formation of an inactive ternary complex [72]. Importantly, sgp130 (soluble glycoprotein 130) is not believed to inhibit signalling by other cytokines that act via gp130 [61]. Under normal circumstances, IL-6 is present at low picogram levels, considerably lower than either sIL-6R (∼75 ng/ml) or sgp130 (250–400 ng/ml). Consequently, Rose-John [73] has suggested that IL-6 is buffered by soluble factors that either promote (sIL-6R) or hinder (sIL-6R + sgp130) trans-signalling. Importantly, this buffering system may become dysregulated in inflammatory states in which circulating IL-6 levels can rise to achieve comparable levels to sIL-6R and sgp130 [74].

IL-6 lies at the heart of cancer-associated inflammation

In recent decades, several studies have linked chronic inflammation with the development of various malignancies, implicating IL-6 in this process [75,76]. Interleukin-6 is a crucial mediator of inflammation and can be found in substantial levels within the microenvironment of many cancers [77], including colorectal [78], ovarian [79], breast [80], prostate [81], lung [82], pancreatic [83], head and neck [84], and renal cell carcinomas [85], diverse lymphomas [86] and in multiple myeloma (MM) [87]. In this context, IL-6 may be produced by tumour cells themselves, in addition to infiltrating stromal cells of mesenchymal and haematological origin (e.g. macrophages and T cells) [77]. A key factor that drives IL-6 release in this context is the nuclear factor-kappa B (NF-κB) transcription factor, which is aberrantly hyperactivated in many cancers [88,89].

Within the tumour microenvironment, IL-6 can promote several pro-tumourigenic activities, including enhanced survival, growth, invasion and angiogenesis (described further below for individual cancer types). Additional effects of IL-6 include the activation of stromal fibroblasts [90], inhibition of type 1 immune responses [91], enhancement of the ratio of intra-tumoural regulatory to CD8+ T-cell types [92], enhanced generation of immunosuppressive myeloid cell subsets at the expense of dendritic cells [61,93], inhibition of natural killer cell function [94], and induction of epithelial-to-mesenchymal transition [95]. Further discussion of the association of IL-6 with different immune cells are covered in the reviews [96,97].

Colorectal cancer

Komoda et al. [98] showed that IL-6 levels in malignant tissues of 32 patients diagnosed with colorectal cancer (CRC) were significantly higher compared with normal colorectal tissues, concluding that IL-6 might have a role in tumour growth. Furthermore, Zeng et al. [99] reported that IL-6 can be a useful prognostic indicator since expression was significantly higher in CRC tissues compared with noncancerous tissues. Elevated serum levels of IL-6 have also been correlated with poorer disease outcome in CRC [100]. In addition, increased IL-6 correlates with enhanced phosphorylation of STAT3 in CRC cells, but not in normal colon epithelium [101]. The effect of IL-6 on CRC is most likely mediated through trans-signalling since Becker et al. [102] showed that sIL-6R was highly induced during tumorigenesis, while mbIL-6R was barely detected. This was further confirmed by detecting increased expression of ADAM17 on tumour cells compared with normal cells, an enzyme that is known to efficiently cleave mbIL-6R, releasing sIL-6R. More recently, Rose-John and colleagues have implicated IL-6 trans-signalling in a mouse model of colorectal cancer, acting downstream of epidermal growth factor signalling in myeloid cells [103].

Ovarian carcinoma

Patients with advanced epithelial ovarian cancer (EOC) commonly have impaired immune function that is associated with elevated serum levels of pro-inflammatory molecules, including IL-6 [104]. Several studies have implicated IL-6 in EOC progression [105], chemotherapy resistance [106], and poorer survival [107,108]. Levels of IL-6 are substantially elevated in the cystic fluid and ascites of advanced malignant compared with benign ovarian tumours and levels correlate with tumour size and volume of ascites [109111].

Evidence suggests that IL-6 may play a direct role in facilitating ovarian tumour progression. One mechanism that may contribute to this is the up-regulated expression of anti-apoptotic molecules, including Bcl-2 (B-cell lymphoma 2) and Bcl-xl, that favour enhanced survival of EOC cells [79]. Moreover, Wang et al. [112] demonstrated that IL-6 alters cell cycle distribution of ovarian cancer cells. Rabinovich et al. [113] demonstrated that IL-6 can also induce the secretion of matrix metalloproteinase-9 (MMP-9), augmenting the invasiveness of ovarian tumour cells. The addition of anti-IL-6 antibodies to SKOV-3 ovarian cancer cells resulted in reduced MMP-9 levels compared with control cultures.

Interleukin-6 has also been shown to act as a potent pro-angiogenic factor in different ovarian cancer models [114]. In addition, increased production of secreted sIL-6R by ovarian cancer cells has been reported, most notably by SKOV-3 cells [114]. This raises the possibility that IL-6 trans-signalling is involved in inducing tumour angiogenesis in ovarian cancers.

Breast cancer

In vitro studies of the effects of IL-6 on breast cancer cell lines have yielded inconsistent results, demonstrating tumour-promoting activities in some models and tumour-suppressing actions in others. Illustrating this, IL-6 was detected in high quantities in supernatants of MCF-7/adriamycin multidrug-resistant breast cancer cells, whereas the cytokine was not detectable in the supernatants of the parental sensitive cells. Furthermore, the addition of exogenous IL-6 to MCF-7 cells caused an 8- to 10-fold increase in their resistance to doxorubicin treatment, while MCF-7 cells that had been engineered to produce IL-6 showed a 70-fold increase in their resistance to multiple drugs [115]. The addition of exogenous IL-6 to MDA-MB-231 triple-negative breast cancer cells induced the production of G96, a protein related to drug resistance. In keeping with this, the authors found that both IL-6 and G96 proteins were considerably increased in breast tumours in comparison with non-malignant breast tissues [116]. Nonetheless, other studies suggest that IL-6 may exert anti-tumour activity against some breast cancers. For example, IL-6 has been reported to induce apoptosis of MCF7 breast cancer cells in some studies [117,118]. In alignment with these findings, Shen et al. [119] demonstrated that along with IL-6, IL-1β and tumour necrosis factor (TNF)-α inhibited the proliferation of MCF-7 cells via suppression of insulin-like growth factor-I (IGF-I), a factor that is known to induce DNA synthesis in this cell type.

Regardless of its controversial role in breast cancer proliferation and survival, IL-6 can promote the migration of breast malignant cells, suggesting a role in metastasis [120,121]. The addition of IL-6-stimulated breast cancer cell spreading via induction of the transition from a stationary to motile phenotype [122]. Another study indicated that IL-6 has anti-adhesive effects on breast cancer cells, a finding that was linked to reduced expression of E-cadherin by the tumour cells [123].

Although different studies have shown divergent results regarding the utility of IL-6 levels in breast tumour tissue as a prognostic factor [124127], elevated serum IL-6 levels have been linked to negative prognosis in this disease. When compared with healthy women, serum IL-6 levels were significantly elevated in breast cancer patients and were correlated with the clinical stage of disease [128]. Zhang and Adachi [129] demonstrated that patients with widely metastatic breast cancer had significantly increased serum IL-6 levels compared with patients with a single metastatic site only. They also reported that patients with higher levels of IL-6 had inferior response to chemo-endocrine therapy as well as reduced survival. Supporting these findings, other studies have linked the presence of increased levels of serum IL-6 in metastatic breast cancer patients with poorer progression-free and overall survival [130132]. Levels of IL-6 were also notably higher in patients with recurrent compared with non-recurrent breast cancer. A similar increase was noted in patients with progressive recurrent disease in comparison with stable recurrent cases, indicating the potential use of IL-6 as a negative prognostic marker [133,134].

Other types of cancer

It is beyond the scope of this mini-review to provide a detailed summary of the role of IL-6 signalling in all types of cancer, although a brief overview is provided for completeness. In prostate cancer, similarly discordant findings to those obtained in breast cancer have been obtained with respect to the role of this cytokine in tumour cell apoptosis [135,136], although once again, IL-6 has also been linked to increased tumour cell invasiveness and metastasis [137139].

Similarly, investigations have shown that IL-6 levels are increased in lung cancer patients, activating JAK2–STAT3 signalling pathway which in turn promotes tumour progression, drug resistance, and poor survival of patients [140143].

In pancreatic cancer, serum IL-6 levels have been proposed as a prognostic marker while intra-tumoural activation of a JAK–STAT3 pathway was linked to particularly poor prognosis [144,145]. The ability of IL-6 to activate Pim-I kinase in pancreatic cancer has also been linked to enhanced tumour cell survival and treatment resistance [146,147]. The involvement of IL-6 trans-signalling was also described in promoting pancreatic ductal adenocarcinoma development [148].

Comparable findings were found in squamous cell carcinoma of head and neck where increased concentrations of IL-6 were correlated with advanced stage of disease [84]. Duffy et al. [149] performed a study on 444 patients and concluded that serum IL-6 alone is a useful predictive marker of disease recurrence and poor prognosis. Tumour progression in this context has been linked to IL-6-mediated STAT3 activation [150].

In renal cell carcinoma (RCC), it was found that many cell lines constitutively secrete IL-6, resulting in enhanced proliferation and tumour progression. Furthermore, in the presence of a mutated TP53 (tumour protein-53) gene, IL-6 was secreted at greater levels [151]. Activated STAT3 not only induces cell proliferation but also up-regulates the expression of vascular endothelial growth factor (VEGF) by activating hypoxia-induced factor-1 alpha (HIF-1α), thus promoting angiogenesis [152].

In haematological malignancies such as lymphoma and multiple myeloma, IL-6 is produced by the malignant cells themselves and bone marrow stromal cells. Moreover, IL-6 is produced by germinal centre B cells in Castleman's disease (CD) [153155]. Similar to solid tumours, IL-6 regulates different signalling pathways that include Ras/Raf/MAPK pathway, PI3K/AKT pathway, and most importantly STAT3. In turn, this promotes cell survival and migratory phenotype, therapeutic resistance, angiogenesis, and metastasis [156158]. Elevation of serum IL-6 and sIL-6R were also documented in non-Hodgkin's lymphomas (NHL), Hodgkin's disease (HD), and in adult T-cell leukaemia, potentially contributing to disease prognosis [159].

Targeting the IL-6/IL-6R axis in cancer

Since evidence implicates aberrant IL-6 production in the pathophysiology of various malignancies and chronic inflammatory diseases, inhibition of IL-6 signalling may provide a therapeutic opportunity in these disease types. This can be achieved by targeting the cytokine itself, IL-6 receptors, or the signalling pathways that are activated as a consequence. Many different strategies to achieve these goals have been developed in recent decades. In an early study, Klein et al. [155,160] demonstrated that a mouse anti-IL-6 monoclonal antibody (mAb) named B-E8 could inhibit malignant cell proliferation in patients with multiple myeloma. Furthermore, the mAb abrogated fever and normalised body temperature with no major adverse effects. Moreover, C-reactive protein (CRP), whose production is controlled by IL-6, was no longer detected in the circulation after treatment commencing, providing a potential marker for therapy efficacy. Through binding to IL-6, B-E8 prevents interaction with IL-6R and therefore inhibits active receptor complex assembly [161]. A less immunogenic chimeric mAb with enhanced half-life called siltuximab (CNTO 328) was subsequently developed and has been evaluated in patients with MM, CD, NHL, prostate cancer, and renal cancer, with promising results in many cases [162167]. In 2014, siltuximab was approved by the United States Food and Drug Administration (FDA) for the treatment of multicentric CD [168,169].

A strategy of blocking IL-6 signalling by preventing the formation of the active signalling complex has been achieved using human IgG1 Fc-tagged recombinant soluble gp130, namely olamkicept [72,73]. By binding to the IL-6/sIL-6R complex, it selectively inhibits trans-signalling that would otherwise arise following binding to membrane-bound gp130. In vivo testing has shown efficacy in different diseases including inflammation-induced cancer and Phase II trials are currently ongoing in this respect [68,72,73]. Moreover, there are two ongoing Phase II clinical trials of this blocking agent that are ongoing in patients with active inflammatory bowel disease [170,171].

Tocilizumab is a humanised mAb that blocks IL-6 signalling by interacting with both the membrane-bound and soluble forms of IL-6R, thereby preventing interaction with IL-6 [172,173]. This treatment has demonstrated significant efficacy in various diseases including CD [174] and rheumatoid arthritis [175], leading to FDA-approval for patients with rheumatoid arthritis and giant cell arteritis [176]. Notably, tocilizumab has also been approved by the FDA for use in patients who develop cytokine release syndrome (CRS) following treatment with chimeric antigen receptor (CAR)-engineered T-cells [177] — a scenario in which macrophage-derived IL-6 signalling has been shown to be pivotal [178180]. Several studies are ongoing to investigate the activity of tocilizumab in different cancer types.

Signal transduction downstream of IL-6 may also be antagonised using many approaches. Small molecule tyrosine kinase inhibitors have been designed that preferentially antagonise JAK1 and JAK3. Tofacitinib is such a molecule and has been approved by the FDA for the treatment of rheumatoid arthritis and ulcerative colitis [181]. As for malignancies, Ruxolitinib, which selectively targets JAK1 and JAK2, was approved by the FDA for the treatment of myelofibrosis and polycythaemia vera [182]. Alternatively, STAT3 inhibitors are currently undergoing clinical evaluation in many disease indications [61]. The targeting of IL-6, its associated receptors and downstream pathways, is further discussed in several comprehensive reviews [97,182].

To date, most of the strategies used to block the IL-6/IL-6R axis have focused on inflammatory and myeloproliferative disorders rather than solid tumours, as indicated above. Therefore, more studies are needed to incorporate such agents with conventional treatment plans, including chemotherapy and radiotherapy, or with more recently developed therapies, such as immune checkpoint inhibitors. In fact, combination immunotherapy using anti-IL-6 antibody and PD-L1 blockade has shown a synergistic antitumour effect in murine models of hepatocellular carcinoma cancer, pancreatic cancer, and melanoma [91,183,184], providing a rationale for related clinical studies.

Conclusions

Overexpression of IL-6 has been identified in numerous types of cancer, leading to the dysregulation of a plethora of cellular activities that generally promote tumour progression. Strategies aimed at blocking IL-6 signalling may provide a potential therapeutic strategy for multiple malignancies, most likely as a component of a combinatorial therapeutic strategy. Further studies are needed to clarify the exact roles of classic versus trans-signalling in these actions of IL-6, since this may provide a rationale for more targeted inhibition of the function of this pleiotropic cytokine.

Abbreviations

     
  • CD

    Castleman's disease

  •  
  • CRC

    colorectal cancer

  •  
  • EOC

    epithelial ovarian cancer

  •  
  • FERM domain

    Band-4.1, ezrin, radixin, moesin

  •  
  • gp130

    glycoprotein 130

  •  
  • Ig

    immunoglobulin

  •  
  • IL

    interleukin

  •  
  • IL-6Rα

    interleukin-6 receptor alpha

  •  
  • JAK

    Janus tyrosine kinase

  •  
  • mAb

    monoclonal antibody

  •  
  • MAPK

    mitogen-activated protein kinase

  •  
  • mbIL-6R

    membrane-bound IL-6 receptor

  •  
  • MM

    multiple myeloma

  •  
  • MMP-9

    matrix metalloproteinase-9

  •  
  • NHL

    non-Hodgkin's lymphomas

  •  
  • PI3K

    phosphatidylinositol 3-kinase

  •  
  • sgp130

    soluble glycoprotein 130

  •  
  • sIL-6R

    soluble IL-6 receptor

  •  
  • SOCS

    suppressor of cytokine signalling

  •  
  • STAT

    signal transducers and activators of transcription

Funding

Research in J.M.'s laboratory is supported by the Medical Research Council, Cancer Research UK, Bayer HealthCare, Bloodwise, the King's Health Partners Research and Development Fund, British Council Newton Fund Institutional Links Award, the British Lung Foundation, Breast Cancer Now, the Experimental Cancer Medicine Centre at King's College London, the King's Health Partners Cancer Research UK Cancer Centre and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London.

Acknowledgments

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. J.M. is chief scientific officer of Leucid Bio, a spinout company focused on CAR T-cell and Vγ9Vδ2 T-cell immunotherapies for malignant disease. M.Y.T. was sponsored by the Saudi Arabian Cultural Bureau.

Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

References

References
1
Kishimoto
,
T.
,
Hirano
,
T.
,
Kuritani
,
T.
,
Yamamura
,
Y.
,
Ralph
,
P.
and
Good
,
R.A.
(
1978
)
Induction of IgG production in human B lymphoblastoid cell lines with normal human T cells
.
Nature
271
,
756
758
2
Howard
,
M.
,
Farrar
,
J.
,
Hilfiker
,
M.
,
Johnson
,
B.
,
Takatsu
,
K.
,
Hamaoka
,
T.
et al. 
(
1982
)
Identification of a T cell-derived b cell growth factor distinct from interleukin 2
.
J. Exp. Med.
155
,
914
923
3
Hirano
,
T.
,
Yasukawa
,
K.
,
Harada
,
H.
,
Taga
,
T.
,
Watanabe
,
Y.
,
Matsuda
,
T.
et al. 
(
1986
)
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
.
Nature
324
,
73
76
4
Zilberstein
,
A.
,
Ruggieri
,
R.
,
Korn
,
J.H.
and
Revel
,
M.
(
1986
)
Structure and expression of cDNA and genes for human interferon-β-2, a distinct species inducible by growth-stimulatory cytokines
.
EMBO J.
5
,
2529
2537
5
Gauldie
,
J.
,
Richards
,
C.
,
Harnish
,
D.
,
Lansdorp
,
P.
and
Baumann
,
H.
(
1987
)
Interferon β 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells
.
Proc. Natl Acad. Sci. U.S.A.
84
,
7251
7255
6
Shabo
,
Y.
,
Lotem
,
J.
,
Rubinstein
,
M.
,
Revel
,
M.
,
Clark
,
S.C.
,
Wolf
,
S.F.
et al. 
(
1988
)
The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6
.
Blood
72
,
2070
2073
PMID:
[PubMed]
7
Hirano
,
T.
(
2014
)
Revisiting the 1986 molecular cloning of interleukin 6
.
Front. Immunol.
5
,
456
8
Andus
,
T.
,
Geiger
,
T.
,
Hirano
,
T.
,
Kishimoto
,
T.
,
Tran-Thi
,
T.A.
,
Decker
,
K.
et al. 
(
1988
)
Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/1L-6) in hepatocyte primary cultures
.
Eur. J. Biochem.
173
,
287
293
9
Itoh
,
N.
,
Matsuda
,
T.
,
Ohtani
,
R.
and
Okamoto
,
H.
(
1989
)
Angiotensinogen production by rat hepatoma cells is stimulated by B cell stimulatory factor 2/interleukin-6
.
FEBS Lett.
244
,
6
10
10
Hirano
,
T.
,
Taga
,
T.
,
Matsuda
,
T.
,
Hibi
,
M.
,
Suematsu
,
S.
,
Tang
,
B.
et al. 
(
1990
)
Interleukin 6 and its receptor in the immune response and hematopoiesis
.
Int. J. Cell Cloning
8
,
155
167
11
Bettelli
,
E.
,
Carrier
,
Y.
,
Gao
,
W.
,
Korn
,
T.
,
Strom
,
T.B.
,
Oukka
,
M.
et al. 
(
2006
)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
.
Nature
441
,
235
238
12
Tanaka
,
T.
,
Narazaki
,
M.
and
Kishimoto
,
T.
(
2014
)
IL-6 in inflammation, immunity, and disease
.
Cold Spring Harb. Perspect. Biol.
6
,
a016295
13
Glund
,
S.
,
Deshmukh
,
A.
,
Long
,
Y.C.
,
Moller
,
T.
,
Koistinen
,
H.A.
,
Caidahl
,
K.
et al. 
(
2007
)
Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle
.
Diabetes
56
,
1630
1637
14
Kanda
,
T.
and
Takahashi
,
T.
(
2004
)
Interleukin-6 and cardiovascular diseases
.
Jpn Heart J.
45
,
183
193
15
Ji
,
C.
,
Chen
,
X.
,
Gao
,
C.
,
Jiao
,
L.
,
Wang
,
J.
,
Xu
,
G.
et al. 
(
2011
)
IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes
.
J. Bioenerg. Biomembr.
43
,
367
375
16
Kim
,
J.
,
Bachmann
,
R.A.
and
Chen
,
J.
(
2009
)
Interleukin-6 and insulin resistance
.
Vitam. Horm.
80
,
613
633
17
Rohleder
,
N.
,
Aringer
,
M.
and
Boentert
,
M.
(
2012
)
Role of interleukin-6 in stress, sleep, and fatigue
.
Ann. N. Y. Acad. Sci.
1261
,
88
96
18
Papanicolaou
,
D.A.
(
2000
)
Interleukin-6: the endocrine cytokine
.
J. Clin. Endocrinol. Metab.
85
,
1331
1333
19
Hirano
,
T.
,
Taga
,
T.
,
Yasukawa
,
K.
,
Nakajima
,
K.
,
Nakano
,
N.
,
Takatsuki
,
F.
et al. 
(
1987
)
Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production
.
Proc. Natl Acad. Sci. U.S.A.
84
,
228
231
20
Hirano
,
T.
,
Matsuda
,
T.
,
Turner
,
M.
,
Miyasaka
,
N.
,
Buchan
,
G.
,
Tang
,
B.
et al. 
(
1988
)
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
.
Eur. J. Immunol.
18
,
1797
1802
21
Hodge
,
D.R.
,
Hurt
,
E.M.
and
Farrar
,
W.L.
(
2005
)
The role of IL-6 and STAT3 in inflammation and cancer
.
Eur. J. Cancer
41
,
2502
2512
22
Schafer
,
Z.T.
and
Brugge
,
J.S.
(
2007
)
IL-6 involvement in epithelial cancers
.
J. Clin. Invest.
117
,
3660
3663
23
Fisher
,
D.T.
,
Appenheimer
,
M.M.
and
Evans
,
S.S.
(
2014
)
The two faces of IL-6 in the tumor microenvironment
.
Semin. Immunol.
26
,
38
47
24
Bazan
,
J.F.
(
1990
)
Structural design and molecular evolution of a cytokine receptor superfamily (hematopoietic system/interferon/tissue factor/flbronectin/immunoglobulin)
.
Biochemistry
87
,
6934
6938
PMID:
[PubMed]
25
Bazan
,
J.F.
(
1990
)
Haemopoietic receptors and helical cytokines
.
Immunol. Today
11
,
350
354
26
Grotzinger
,
J.
,
Kurapkat
,
G.
,
Wollmer
,
A.
,
Kalai
,
M.
and
Rose-John
,
S.
(
1997
)
The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes
.
Proteins Struct. Funct. Genet.
27
,
96
109
27
Brakenhoff
,
J.P.
,
Hart
,
M.
,
De Groot
,
E.R.
,
Di Padova
,
F.
and
Aarden
,
L.A.
(
1990
)
Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants
.
J. Immunol.
145
,
561
568
PMID:
[PubMed]
28
Brakenhoff
,
J.P.
,
de Hon
,
F.D.
,
Fontaine
,
V.
,
ten Boekel
,
E.
,
Schooltink
,
H.
,
Rose-John
,
S.
et al. 
(
1994
)
Development of a human interleukin-6 receptor antagonist
.
J. Biol. Chem.
269
,
86
93
PMID:
[PubMed]
29
Ehlers
,
M.
,
Grötzinger
,
J.
,
deHon
,
F.D.
,
Müllberg
,
J.
,
Brakenhoff
,
J.P.
,
Liu
,
J.
et al. 
(
1994
)
Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction
.
J. Immunol.
153
,
1744
1753
PMID:
[PubMed]
30
Savino
,
R.
,
Lahm1
,
A.
,
Salvati
,
A.L.
,
Ciapponi
,
L.
,
Sporeno
,
E.
,
Altamura
,
S.
et al. 
(
1994
)
Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation
.
EMBO J.
13
,
1357
1367
31
Savino
,
R.
,
Lciapponi
,
A.
,
Lahm1
,
A.
,
Demartis
,
A.
,
Cabibbo
,
C.
,
Toniatti
,
S.
et al. 
(
1994
)
Rational design of a receptor super-antagonist of human interleukin-6
.
EMBO J.
13
,
5863
5870
32
Paonessa
,
G.
,
Graziani
,
R.
,
De Serio
,
A.
,
Savino
,
R.
,
Ciapponi
,
L.
,
Lahm
,
A.
et al. 
(
1995
)
Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling
.
EMBO J.
14
,
1942
1951
33
Chow
,
D.
,
Brevnova
,
L.
,
He
,
X.
,
Martick
,
M.M.
,
Bankovich
,
A.
and
Garcia
,
K.C.
(
2002
)
A structural template for gp130-cytokine signaling assemblies
.
Biochim. Biophys. Acta, Mol. Cell Res.
1592
,
225
235
34
Boulanger
,
M.J.
,
Chow
,
D.
,
Brevnova
,
E.E.
and
Garcia
,
K.C.
(
2003
)
Hexameric structure and assembly of the interleukin-6/IL-6-receptor/gp130 complex
.
Science
300
,
2101
2104
35
Yawata
,
H.
,
Yasukawa
,
K.
,
Natsuka
,
S.
,
Murakami
,
M.
,
Yamasaki
,
K.
,
Hibi
,
M.
et al. 
(
1993
)
Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130
.
EMBO J.
12
,
1705
1712
36
Lahm
,
A.
,
Savino
,
R.
,
Salvati
,
A.L.
,
Cabibbo
,
A.
,
Ciapponi
,
L.
,
Demartis
,
A.
et al. 
(
1995
)
The molecular design of human IL-6 receptor antagonists
.
Ann. N. Y. Acad. Sci.
762
,
136
150
37
Nimo Bravo
,
J.
,
Staunton
,
D.
,
Heath
,
J.K.
and
Jones
,
E.Y.
(
1998
)
Crystal structure of a cytokine-binding region of gp130
.
EMBO J.
17
,
1665
1674
38
Chow
,
D.-C.
,
Ho
,
J.
,
Linh
,
T.
,
Pham
,
N.
,
Rose-John
,
S.
and
Garcia
,
K.C.
(
2001
)
In vitro reconstitution of recognition and activation complexes between interleukin-6 and gp130
.
Biochemistry
40
,
7593
7603
39
Chow
,
D.C.
,
He
,
X.
,
Snow
,
A.L.
,
Rose-John
,
S.
and
Garcia
,
K.C.
(
2001
)
Structure of an extracellular gp130 cytokine receptor signaling complex
.
Science
291
,
2150
2155
40
Taga
,
T.
,
Hibi
,
M.
,
Hirata
,
Y.
,
Yamasaki
,
K.
,
Yasukawa
,
K.
,
Matsuda
,
T.
et al. 
(
1989
)
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
.
Cell
58
,
573
581
41
Yamasaki
,
K.
,
Taga
,
T.
,
Hirata
,
Y.
,
Yawata
,
H.
,
Kawanishi
,
Y.
,
Seed
,
B.
et al. 
(
1988
)
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor
.
Science
241
,
825
828
42
Sprang
,
S.R.
and
Fernando Bazan
,
J.
(
1993
)
Cytokine structural taxonomy and mechanisms of receptor engagement
.
Curr. Opin. Struct. Biol.
3
,
815
827
43
Hibi
,
M.
,
Murakami
,
M.
,
Saito
,
M.
,
Hirano
,
T.
,
Taga
,
T.
and
Kishimoto
,
T.
(
1990
)
Molecular cloning and expression of an IL-6 signal transducer, gp130
.
Cell
63
,
1149
1157
44
Ward
,
L.D.
,
Howlett
,
G.J.
,
Discolo
,
G.
,
Yasukawa
,
K.
,
Hammacher
,
A.
,
Moritz
,
R.L.
et al. 
(
1994
)
High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130
.
J. Biol. Chem.
269
,
23286
9
PMID:
[PubMed]
45
Grötzinger
,
J.
,
Kernebeck
,
T.
,
Kallen
,
K.-J.
and
Rose-John
,
S.
(
1999
)
IL-6 type cytokine receptor complexes: hexamer, tetramer or both?
Biol. Chem.
380
,
803
813
46
Nakajima
,
T.
,
Kinoshita
,
S.
,
Sasagawa
,
T.
,
Sasaki
,
K.
,
Naruto
,
M.
,
Kishimoto
,
T.
et al. 
(
1993
)
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6
.
Proc. Natl Acad. Sci. U.S.A.
90
,
2207
2211
47
Satoh
,
T.
,
Nakafuku
,
M.
and
Kaziro
,
Y.
(
1992
)
Function of Ras as a molecular switch in signal transduction
.
J. Biol. Chem.
267
,
24149
24152
PMID:
[PubMed]
48
Lütticken
,
C.
,
Wegenka
,
U.M.
,
Yuan
,
J.
,
Buschmann
,
J.
,
Schindler
,
C.
,
Ziemiecki
,
A.
et al. 
(
1994
)
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130
.
Science
263
,
89
92
49
David
,
M.
,
Petricoin
,
E.
,
Benjamin
,
C.
,
Pine
,
R.
,
Weber
,
M.J.
and
Larner
,
A.C.
(
1995
)
Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins
.
Science
269
,
1721
1723
50
Zhang
,
X.
,
Blenis
,
J.
,
Li
,
H.C.
,
Schindler
,
C.
and
Chen-Kiang
,
S.
(
1995
)
Requirement of serine phosphorylation for formation of STAT-promoter complexes
.
Science
267
,
1990
1994
51
Taniguchi
,
K.
,
Wu
,
L.-W.
,
Grivennikov
,
S.I.
,
de Jong
,
P.R.
,
Lian
,
I.
,
Yu
,
F.-X.
et al. 
(
2015
)
A gp130–Src–YAP module links inflammation to epithelial regeneration
.
Nature
519
,
57
62
52
Taniguchi
,
K.
,
Moroishi
,
T.
,
de Jong
,
P.R.
,
Krawczyk
,
M.
,
Grebbin
,
B.M.
,
Luo
,
H.
et al. 
(
2017
)
YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis
.
Proc. Natl Acad. Sci. U.S.A.
114
,
1643
1648
53
Zhou
,
Y.J.
,
Chen
,
M.
,
Cusack
,
N.A.
,
Kimmel
,
L.H.
,
Magnuson
,
K.S.
,
Boyd
,
J.G.
et al. 
(
2001
)
Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases
.
Mol. Cell
8
,
959
969
54
Heinrich
,
P.C.
,
Behrmann
,
I.
,
Haan
,
S.
,
Hermanns
,
H.M.
,
Müller-Newen
,
G.
and
Schaper
,
F.
(
2003
)
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
.
Biochem. J.
374
,
1
20
55
Schaper
,
F.
and
Rose-John
,
S.
(
2015
)
Interleukin-6: biology, signaling and strategies of blockade
.
Cytokine Growth Factor Rev.
26
,
475
487
56
Schmitz
,
J.
,
Dahmen
,
H.
,
Grimm
,
C.
,
Gendo
,
C.
,
Müller-Newen
,
G.
,
Heinrich
,
P.C.
et al. 
(
2000
)
The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction
.
J. Immunol.
164
,
848
854
57
Chang
,
Q.
,
Bournazou
,
E.
,
Sansone
,
P.
,
Berishaj
,
M.
,
Gao
,
S.P.
,
Daly
,
L.
et al. 
(
2013
)
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
.
Neoplasia
15
,
848
862
58
Schmitz
,
J.
,
Weissenbach
,
M.
,
Haan
,
S.
,
Heinrich
,
P.C.
and
Schaper
,
F.
(
2000
)
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130
.
J. Biol. Chem.
275
,
12848
12856
59
Jenkins
,
B.J.
,
Grail
,
D.
,
Nheu
,
T.
,
Najdovska
,
M.
,
Wang
,
B.
,
Waring
,
P.
et al. 
(
2005
)
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling
.
Nat. Med.
11
,
845
852
60
Ernst
,
M.
,
Najdovska
,
M.
,
Grail
,
D.
,
Lundgren-May
,
T.
,
Buchert
,
M.
,
Tye
,
H.
et al. 
(
2008
)
STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice
.
J. Clin. Invest.
118
,
1727
1738
61
Johnson
,
D.E.
,
O'Keefe
,
R.A.
and
Grandis
,
J.R.
(
2018
)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
.
Nat. Rev. Clin. Oncol.
15
,
234
248
62
Novick
,
D.
,
Engelmann
,
H.
,
Wallach
,
D.
and
Rubinstein
,
M.
(
1989
)
Soluble cytokine receptors are present in normal human urine
.
J. Exp. Med.
170
,
1409
1414
63
Mülberg
,
J.
,
Schooltink
,
H.
,
Stoyan
,
T.
,
Günther
,
M.
,
Graeve
,
L.
,
Buse
,
G.
et al. 
(
1993
)
The soluble interleukin-6 receptor is generated by shedding
.
Eur. J. Immunol.
23
,
473
480
64
Lust
,
J.A.
,
Donovan
,
K.A.
,
Kline
,
M.P.
,
Greipp
,
P.R.
,
Kyle
,
R.A.
and
Maihle
,
N.J.
(
1992
)
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
.
Cytokine
4
,
96
100
65
Riethmueller
,
S.
,
Somasundaram
,
P.
,
Ehlers
,
J.C.
,
Hung
,
C.-W.
,
Flynn
,
C.M.
,
Lokau
,
J.
et al. 
(
2017
)
Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation
.
PLoS Biol.
15
,
e2000080
66
Scheller
,
J.
and
Rose-John
,
S.
(
2006
)
Interleukin-6 and its receptor: from bench to bedside
.
Med. Microbiol. Immunol.
195
,
173
183
67
Rose-John
,
S.
and
Heinrich
,
P.C.
(
1994
)
Soluble receptors for cytokines and growth factors: generation and biological function
.
Biochem. J.
300
,
281
290
68
Rabe
,
B.
,
Chalaris
,
A.
,
May
,
U.
,
Waetzig
,
G.H.
,
Seegert
,
D.
,
Williams
,
A.S.
et al. 
(
2007
)
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation
.
Blood
111
,
1021
1028
69
Scheller
,
J.
,
Chalaris
,
A.
,
Schmidt-Arras
,
D.
and
Rose-John
,
S.
(
2011
)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
.
Biochim. Biophys. Acta, Mol. Cell Res.
1813
,
878
888
70
Heink
,
S.
,
Yogev
,
N.
,
Garbers
,
C.
,
Herwerth
,
M.
,
Aly
,
L.
,
Gasperi
,
C.
et al. 
(
2017
)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
.
Nat. Immunol.
18
,
74
85
71
Narazaki
,
M.
,
Yasukawa
,
K.
,
Saito
,
T.
,
Ohsugi
,
Y.
,
Fukui
,
H.
,
Koishihara
,
Y.
et al. 
(
1993
)
Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
.
Blood
82
,
1120
1126
PMID:
[PubMed]
72
Jostock
,
T.
,
Müllberg
,
J.
,
Özbek
,
S.
,
Atreya
,
R.
,
Blinn
,
G.
,
Voltz
,
N.
et al. 
(
2001
)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
.
Eur. J. Biochem.
268
,
160
167
73
Rose-John
,
S.
(
2012
)
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6
.
Int. J. Biol. Sci.
8
,
1237
1247
74
Baran
,
P.
,
Hansen
,
S.
,
Waetzig
,
G.H.
,
Akbarzadeh
,
M.
,
Lamertz
,
L.
,
Huber
,
H.J.
et al. 
(
2018
)
The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling
.
J. Biol. Chem.
293
,
6762
6775
75
Balkwill
,
F.
and
Mantovani
,
A.
(
2001
)
Inflammation and cancer: back to Virchow?
Lancet
357
,
539
545
76
Bromberg
,
J.
and
Wang
,
T.C.
(
2009
)
Inflammation and cancer: IL-6 and STAT3 complete the link
.
Cancer Cell
15
,
79
80
77
Grivennikov
,
S.I.
and
Karin
,
M.
(
2011
)
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
.
Ann. Rheum. Dis.
70
,
i104
i108
78
Waldner
,
M.J.
,
Foersch
,
S.
and
Neurath
,
M.F.
(
2012
)
Interleukin-6—a key regulator of colorectal cancer development
.
Int. J. Biol. Sci.
8
,
1248
1253
79
Macciò
,
A.
and
Madeddu
,
C.
(
2013
)
The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review
.
J. Mol. Med.
91
,
1355
1368
80
Dethlefsen
,
C.
,
Højfeldt
,
G.
and
Hojman
,
P.
(
2013
)
The role of intratumoral and systemic IL-6 in breast cancer
.
Breast Cancer Res. Treat.
138
,
657
664
81
Culig
,
Z.
and
Puhr
,
M.
(
2012
)
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer
.
Mol. Cell Endocrinol.
360
,
52
58
82
Chang
,
C.H.
,
Hsiao
,
C.F.
,
Yeh
,
Y.M.
,
Chang
,
G.C.
,
Tsai
,
Y.H.
,
Chen
,
Y.M.
et al. 
(
2013
)
Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
.
Int. J. Cancer
132
,
1977
1985
83
Miura
,
T.
,
Mitsunaga
,
S.
,
Ikeda
,
M.
,
Shimizu
,
S.
,
Ohno
,
I.
,
Takahashi
,
H.
et al. 
(
2015
)
Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels
.
Pancreas
44
,
756
763
84
Mojtahedi
,
Z.
,
Khademi
,
B.
,
Hashemi
,
S.B.
,
Abtahi
,
S.M.B.
,
Ghasemi
,
M.A.
,
Fattahi
,
M.J.
et al. 
(
2011
)
Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression
.
Pathol. Oncol. Res.
17
,
7
10
85
Altundag
,
O.
,
Altundag
,
K.
and
Gunduz
,
E.
(
2005
)
Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma
.
J. Clin. Oncol.
23
,
1044
1044
86
Kurzrock
,
R.
,
Redman
,
J.
,
Cabanillas
,
F.
,
Jones
,
D.
,
Rothberg
,
J.
and
Talpaz
,
M.
(
1993
)
Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
.
Cancer Res.
53
,
2118
2122
PMID:
[PubMed]
87
Gadó
,
K.
,
Domján
,
G.
,
Hegyesi
,
H.
and
Falus
,
A.
(
2000
)
Role of interleukin-6 in the pathogenesis of multiple myeloma
.
Cell Biol. Int.
24
,
195
209
88
Libermann
,
T.A.
and
Baltimore
,
D.
(
1990
)
Activation of interleukin-6 gene expression through the NF-kappa B transcription factor
.
Mol. Cell Biol.
10
,
2327
2334
89
Yoon
,
S.
,
Woo
,
S.U.
,
Kang
,
J.H.
,
Kim
,
K.
,
Shin
,
H.-J.
,
Gwak
,
H.-S.
et al. 
(
2012
)
NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
.
Oncogene
31
,
3467
3481
90
Karakasheva
,
T.A.
,
Lin
,
E.W.
,
Tang
,
Q.
,
Qiao
,
E.
,
Waldron
,
T.J.
,
Soni
,
M.
et al. 
(
2018
)
IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment
.
Cancer Res.
78
,
4957
4970
91
Tsukamoto
,
H.
,
Fujieda
,
K.
,
Miyashita
,
A.
,
Fukushima
,
S.
,
Ikeda
,
T.
,
Kubo
,
Y.
et al. 
(
2018
)
Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
.
Cancer Res.
78
,
5011
5022
92
Kato
,
T.
,
Noma
,
K.
,
Ohara
,
T.
,
Kashima
,
H.
,
Katsura
,
Y.
,
Sato
,
H.
et al. 
(
2018
)
Cancer-associated fibroblasts affect intratumoral CD8+ and FoxP3+ T cells via IL6 in the tumor microenvironment
.
Clin. Cancer Res.
24
,
4820
4833
93
Hanazawa
,
A.
,
Ito
,
R.
,
Katano
,
I.
,
Kawai
,
K.
,
Goto
,
M.
,
Suemizu
,
H.
et al. 
(
2018
)
Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice
.
Front. Immunol.
9
,
152
94
Gotthardt
,
D.
,
Putz
,
E.M.
,
Straka
,
E.
,
Kudweis
,
P.
,
Biaggio
,
M.
,
Poli
,
V.
et al. 
(
2014
)
Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
.
Blood
124
,
2370
2379
95
Gyamfi
,
J.
,
Lee
,
Y.-H.
,
Eom
,
M.
and
Choi
,
J.
(
2018
)
Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells
.
Sci. Rep.
8
,
8859
96
Mauer
,
J.
,
Denson
,
J.L.
and
Brüning
,
J.C.
(
2015
)
Versatile functions for IL-6 in metabolism and cancer
.
Trends Immunol.
36
,
92
101
97
Jones
,
S.A.
and
Jenkins
,
B.J.
(
2018
)
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
.
Nat. Rev. Immunol.
98
Komoda
,
H.
,
Tanaka
,
Y.
,
Honda
,
M.
,
Matsuo
,
Y.
,
Hazama
,
K.
and
Takao
,
T.
(
1998
)
Interleukin-6 levels in colorectal cancer tissues
.
World J. Surg.
22
,
895
898
99
Zeng
,
J.
,
Tang
,
Z.-H.
,
Liu
,
S.
and
Guo
,
S.-S.
(
2017
)
Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer
.
World J. Gastroenterol.
23
,
1780
1786
100
Chung
,
Y.-C.
and
Chang
,
Y.-F.
(
2003
)
Serum interleukin-6 levels reflect the disease status of colorectal cancer
.
J. Surg. Oncol.
83
,
222
226
101
Corvinus
,
F.M.
,
Orth
,
C.
,
Moriggl
,
R.
,
Tsareva
,
S.A.
,
Wagner
,
S.
,
Pfitzner
,
E.B.
et al. 
(
2005
)
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth
.
Neoplasia
7
,
545
555
102
Becker
,
C.
,
Fantini
,
M.C.
,
Wirtz
,
S.
,
Nikolaev
,
A.
,
Lehr
,
H.A.
,
Galle
,
P.R.
et al. 
(
2005
)
IL-6 signaling promotes tumor growth in colorectal cancer
.
Cell Cycle
217
,
217
220
PMID:
[PubMed]
103
Schmidt
,
S.
,
Schumacher
,
N.
,
Schwarz
,
J.
,
Tangermann
,
S.
,
Kenner
,
L.
,
Schlederer
,
M.
et al. 
(
2018
)
ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
.
J. Exp. Med.
215
,
1205
1225
104
Macciò
,
A.
,
Lai
,
P.
,
Santona
,
M.C.
,
Pagliara
,
L.
,
Melis
,
G.B.
and
Mantovani
,
G.
(
1998
)
High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer
.
Gynecol. Oncol.
69
,
248
252
105
Hagemann
,
T.
,
Robinson
,
S.C.
,
Thompson
,
R.G.
,
Charles
,
K.
,
Kulbe
,
H.
and
Balkwill
,
F.R.
(
2007
)
Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis
.
Mol. Cancer Ther.
6
,
1993
2002
106
Wang
,
Y.
,
Niu
,
X.L.
,
Qu
,
Y.
,
Wu
,
J.
,
Zhu
,
Y.Q.
,
Sun
,
W.J.
et al. 
(
2010
)
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
.
Cancer Lett.
295
,
110
123
107
Scambia
,
G.
,
Testa
,
U.
,
Panici
,
P.B.
,
Martucci
,
R.
,
Foti
,
E.
,
Petrini
,
M.
et al. 
(
1994
)
Interleukin-6 serum levels in patients with gynecological tumors
.
Int. J. Cancer
57
,
318
323
108
Scambia
,
G.
,
Testa
,
U.
,
Benedetti Panici
,
P.
,
Foti
,
E.
,
Martucci
,
R.
,
Gadducci
,
A.
et al. 
(
1995
)
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
.
Br. J. Cancer
71
,
354
356
109
Plante
,
M.
,
Rubin
,
S.C.
,
Wong
,
G.Y.
,
Federici
,
M.G.
,
Finstad
,
C.L.
and
Gastl
,
G.A.
(
1994
)
Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer
.
Cancer
73
,
1882
1888
110
van der Zee
,
A.G.
,
de Cuyper
,
E.M.
,
Limburg
,
P.C.
,
de Bruijn
,
H.W.
,
Hollema
,
H.
,
Bijzet
,
J.
et al. 
(
1995
)
Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts
.
Cancer
75
,
1004
1009
PMID:
[PubMed]
111
Nowak
,
M.
,
Glowacka
,
E.
,
Szpakowski
,
M.
,
Szyllo
,
K.
,
Malinowski
,
A.
,
Kulig
,
A.
et al. 
(
2010
)
Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors
.
Neuro. Endocrinol. Lett.
31
,
375
383
PMID:
[PubMed]
112
Wang
,
Y.
,
Li
,
L.
,
Guo
,
X.
,
Jin
,
X.
,
Sun
,
W.
,
Zhang
,
X.
et al. 
(
2012
)
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells
.
Cytokine
59
,
228
236
113
Rabinovich
,
A.
,
Medina
,
L.
,
Piura
,
B.
,
Segal
,
S.
and
Huleihel
,
M.
(
2007
)
Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6
.
Anticancer Res.
27
,
267
272
PMID:
[PubMed]
114
Nilsson
,
M.B.
,
Langley
,
R.R.
and
Fidler
,
I.J.
(
2005
)
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine
.
Cancer Res.
65
,
10794
10800
115
Conze
,
D.
,
Weiss
,
L.
,
Regen
,
P.S.
,
Bhushan
,
A.
,
Weaver
,
D.
,
Johnson
,
P.
et al. 
(
2001
)
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells
.
Cancer Res.
61
,
8851
8858
PMID:
[PubMed]
116
Haverty
,
A.A.
,
Harmey
,
J.H.
,
Redmond
,
H.P.
and
Bouchier-Hayes
,
D.J.
(
1997
)
Interleukin-6 upregulates GP96 expression in breast cancer
.
J. Surg. Res.
69
,
145
149
117
Danforth
,
D.N.
and
Sgagias
,
M.K.
(
1993
)
Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro
.
Cancer Res.
53
,
1538
1545
PMID:
[PubMed]
118
Chiu
,
J.J.
,
Sgagias
,
M.K.
and
Cowan
,
K.H.
(
1996
)
Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines
.
Clin. Cancer Res.
2
,
215
221
PMID:
[PubMed]
119
Shen
,
W.-H.
,
Zhou
,
J.-H.
,
Broussard
,
S.R.
,
Freund
,
G.G.
,
Dantzer
,
R.
and
Kelley
,
K.W.
(
2002
)
Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor
.
Cancer Res.
62
,
4746
4756
PMID:
[PubMed]
120
Arihiro
,
K.
,
Oda
,
H.
,
Kaneko
,
M.
and
Inai
,
K.
(
2000
)
Cytokines facilitate chemotactic motility of breast carcinoma cells
.
Breast Cancer
7
,
221
230
121
Lin
,
C.
,
Liao
,
W.
,
Jian
,
Y.
,
Peng
,
Y.
,
Zhang
,
X.
,
Ye
,
L.
et al. 
(
2017
)
CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling
.
Oncogene
36
,
3695
3705
122
Verhasselt
,
B.
,
Van Damme
,
J.
,
van Larebeke
,
N.
,
Put
,
W.
,
Bracke
,
M.
,
De Potter
,
C.
et al. 
(
1992
)
Interleukin-1 is a motility factor for human breast carcinoma cells in vitro: additive effect with interleukin-6
.
Eur. J. Cell Biol.
59
,
449
457
PMID:
[PubMed]
123
Ásgeirsson
,
K.S.
,
Ólafsdóttir
,
K.
,
Jónasson
,
J.G.
and
Ögmundsdóttir
,
H.M.
(
1998
)
The effects of IL-6 On cell adhesion and E-cadherin expression in breast cancer
.
Cytokine
10
,
720
728
124
Green
,
A.R.
,
Green
,
V.L.
,
White
,
M.C.
and
Speirs
,
V.
(
1997
)
Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours
.
Int. J. Cancer
72
,
937
941
125
Basolo
,
F.
,
Conaldi
,
P.G.
,
Fiore
,
L.
,
Calvo
,
S.
and
Toniolo
,
A.
(
1993
)
Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma
.
Int. J. Cancer
55
,
926
930
126
Karczewska
,
A.
,
Nawrocki
,
S.
,
Breborowicz
,
D.
,
Filas
,
V.
and
Mackiewicz
,
A.
(
2000
)
Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma
.
Cancer
88
,
2061
2071
PMID:
[PubMed]
127
Purohit
,
A.
,
Ghilchik
,
M.W.
,
Duncan
,
L.
,
Wang
,
D.Y.
,
Singh
,
A.
,
Walker
,
M.M.
et al. 
(
1995
)
Aromatase activity and interleukin-6 production by normal and malignant breast tissues
.
J. Clin. Endocrinol. Metab.
80
,
3052
3058
PMID:
[PubMed]
128
Kozłowski
,
L.
,
Zakrzewska
,
I.
,
Tokajuk
,
P.
and
Wojtukiewicz
,
M.Z.
(
2003
)
Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients
.
Rocz. Akad. Med. Bialymst.
48
,
82
84
PMID:
[PubMed]
129
Zhang
,
G.J.
and
Adachi
,
I.
(
1999
)
Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
.
Anticancer Res.
19
,
1427
1432
PMID:
[PubMed]
130
Bozcuk
,
H.
,
Uslu
,
G.
,
Samur
,
M.
,
Yıldız
,
M.
,
Özben
,
T.
,
Özdoğan
,
M.
et al. 
(
2004
)
Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy
.
Cytokine
27
,
58
65
131
Salgado
,
R.
,
Junius
,
S.
,
Benoy
,
I.
,
Van Dam
,
P.
,
Vermeulen
,
P.
,
Van Marck
,
E.
et al. 
(
2003
)
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
.
Int. J. Cancer
103
,
642
646
132
Bachelot
,
T.
,
Ray-Coquard
,
I.
,
Menetrier-Caux
,
C.
,
Rastkha
,
M.
,
Duc
,
A.
and
Blay
,
J.-Y.
(
2003
)
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
.
Br. J. Cancer
88
,
1721
1726
133
Nishimura
,
R.
,
Nagao
,
K.
,
Miyayama
,
H.
,
Matsuda
,
M.
,
Baba
,
K.
,
Matsuoka
,
Y.
et al. 
(
2000
)
An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer
.
Oncology
59
,
166
173
134
Yokoe
,
T.
,
Iino
,
Y.
and
Morishita
,
Y.
(
2000
)
Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report
.
Breast Cancer
7
,
187
190
135
Okamoto
,
M.
,
Lee
,
C.
and
Oyasu
,
R.
(
1997
)
Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro
.
Cancer Res.
57
,
141
146
PMID:
[PubMed]
136
Chung
,
T.D.
,
Yu
,
J.J.
,
Spiotto
,
M.T.
,
Bartkowski
,
M.
and
Simons
,
J.W.
(
1999
)
Characterization of the role of IL-6 in the progression of prostate cancer
.
Prostate
38
,
199
207
137
Shariat
,
S.F.
,
Chromecki
,
T.F.
,
Hoefer
,
J.
,
Barbieri
,
C.E.
,
Scherr
,
D.S.
,
Karakiewicz
,
P.I.
et al. 
(
2011
)
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner
.
J. Urol.
186
,
2107
2114
138
Shukla
,
S.
,
MacLennan
,
G.T.
,
Hartman
,
D.J.
,
Fu
,
P.
,
Resnick
,
M.I.
and
Gupta
,
S.
(
2007
)
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion
.
Int. J. Cancer
121
,
1424
1432
139
Santer
,
F.R.
,
Malinowska
,
K.
,
Culig
,
Z.
and
Cavarretta
,
I.T.
(
2010
)
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
.
Endocr. Relat. Cancer
17
,
241
253
140
Carpagnano
,
G.E.
,
Resta
,
O.
,
Foschino-Barbaro
,
M.P.
,
Gramiccioni
,
E.
and
Carpagnano
,
F.
(
2002
)
Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer
.
Int. J. Biol. Markers
17
,
141
145
PMID:
[PubMed]
141
Yeh
,
H.-H.
,
Lai
,
W.-W.
,
Chen
,
H.H.W.
,
Liu
,
H.-S.
and
Su
,
W.-C.
(
2006
)
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion
.
Oncogene
25
,
4300
4309
142
Koh
,
E.
,
Iizasa
,
T.
,
Yamaji
,
H.
,
Sekine
,
Y.
,
Hiroshima
,
K.
,
Yoshino
,
I.
et al. 
(
2012
)
Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer
.
Int. J. Surg. Pathol.
20
,
233
239
143
Katsumata
,
N.
,
Eguchi
,
K.
,
Fukuda
,
M.
,
Yamamoto
,
N.
,
Ohe
,
Y.
,
Oshita
,
F.
et al. 
(
1996
)
Serum levels of cytokines in patients with untreated primary lung cancer
.
Clin Cancer Res.
2
,
553
559
PMID:
[PubMed]
144
Denley
,
S.M.
,
Jamieson
,
N.B.
,
McCall
,
P.
,
Oien
,
K.A.
,
Morton
,
J.P.
,
Carter
,
C.R.
et al. 
(
2013
)
Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma
.
J. Gastrointest. Surg.
17
,
887
898
145
Holmer
,
R.
,
Goumas
,
F.A.
,
Waetzig
,
G.H.
,
Rose-John
,
S.
and
Kalthoff
,
H.
(
2014
)
Interleukin-6: a villain in the drama of pancreatic cancer development and progression
.
Hepatobiliary Pancreat. Dis. Int.
13
,
371
380
146
Block
,
K.M.
,
Hanke
,
N.T.
,
Maine
,
E.A.
and
Baker
,
A.F.
(
2012
)
IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines
.
Pancreas
41
,
1
147
Xu
,
J.
,
Xiong
,
G.
,
Cao
,
Z.
,
Huang
,
H.
,
Wang
,
T.
,
You
,
L.
et al. 
(
2016
)
PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value
.
J. Exp. Clin. Cancer Res.
35
,
133
148
Lesina
,
M.
,
Kurkowski
,
M.U.
,
Ludes
,
K.
,
Rose-John
,
S.
,
Treiber
,
M.
,
Klöppel
,
G.
et al. 
(
2011
)
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
.
Cancer Cell
19
,
456
469
149
Duffy
,
S.A.
,
Taylor
,
J.M.G.
,
Terrell
,
J.E.
,
Islam
,
M.
,
Li
,
Y.
,
Fowler
,
K.E.
et al. 
(
2008
)
Interleukin-6 predicts recurrence and survival among head and neck cancer patients
.
Cancer
113
,
750
757
150
Sriuranpong
,
V.
,
Park
,
J.I.
,
Amornphimoltham
,
P.
,
Patel
,
V.
,
Nelkin
,
B.D.
and
Gutkind
,
J.S.
(
2003
)
Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system
.
Cancer Res.
63
,
2948
2956
PMID:
[PubMed]
151
Angelo
,
L.S.
,
Talpaz
,
M.
and
Kurzrock
,
R.
(
2002
)
Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53
.
Cancer Res.
62
,
932
940
PMID:
[PubMed]
152
Jung
,
J.E.
,
Lee
,
H.G.
,
Cho
,
I.H.
,
Chung
,
D.H.
,
Yoon
,
S.-H.
,
Yang
,
Y.M.
et al. 
(
2005
)
STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells
.
FASEB J.
19
,
1296
1298
153
Kawano
,
M.
,
Hirano
,
T.
,
Matsuda
,
T.
,
Taga
,
T.
,
Horii
,
Y.
,
Iwato
,
K.
et al. 
(
1988
)
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
.
Nature
332
,
83
85
154
Yoshizaki
,
K.
,
Matsuda
,
T.
,
Nishimoto
,
N.
,
Kuritani
,
T.
,
Taeho
,
L.
,
Aozasa
,
K.
et al. 
(
1989
)
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
.
Blood
74
,
1360
1367
PMID:
[PubMed]
155
Klein
,
B.
,
Zhang
,
X.G.
,
Jourdan
,
M.
,
Content
,
J.
,
Houssiau
,
F.
,
Aarden
,
L.
et al. 
(
1989
)
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
.
Blood
73
,
517
526
PMID:
[PubMed]
156
Catlett-Falcone
,
R.
,
Landowski
,
T.H.
,
Oshiro
,
M.M.
,
Turkson
,
J.
,
Levitzki
,
A.
,
Savino
,
R.
et al. 
(
1999
)
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
.
Immunity
10
,
105
115
157
Puthier
,
D.
,
Derenne
,
S.
,
Barillé
,
S.
,
Moreau
,
P.
,
Harousseau
,
J.L.
,
Bataille
,
R.
et al. 
(
1999
)
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
.
Br. J. Haematol.
107
,
392
395
158
Hideshima
,
T.
,
Nakamura
,
N.
,
Chauhan
,
D.
and
Anderson
,
K.C.
(
2001
)
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
.
Oncogene
20
,
5991
6000
159
Burger
,
R.
(
2013
)
Impact of interleukin-6 in hematological malignancies
.
Transfus Med. Hemother.
40
,
336
343
160
Klein
,
B.
,
Wijdenes
,
J.
,
Zhang
,
X.G.
,
Jourdan
,
M.
,
Boiron
,
J.M.
,
Brochier
,
J.
et al. 
(
1991
)
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
.
Blood
78
,
1198
1204
PMID:
[PubMed]
161
Kalai
,
M.
,
Montero-Julian
,
F.A.
,
Brakenhoff
,
J.P.
,
Fontaine
,
V.
,
De Wit
,
L.
,
Wollmer
,
A.
et al. 
(
1997
)
Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies
.
Eur. J. Biochem.
249
,
690
700
162
Kurzrock
,
R.
,
Voorhees
,
P.M.
,
Casper
,
C.
,
Furman
,
R.R.
,
Fayad
,
L.
,
Lonial
,
S.
et al. 
(
2013
)
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease
.
Clin. Cancer Res.
19
,
3659
3670
163
Voorhees
,
P.M.
,
Manges
,
R.F.
,
Sonneveld
,
P.
,
Jagannath
,
S.
,
Somlo
,
G.
,
Krishnan
,
A.
et al. 
(
2013
)
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
.
Br. J. Haematol.
161
,
357
366
164
Chari
,
A.
,
Pri-Chen
,
H.
and
Jagannath
,
S.
(
2013
)
Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma
.
Clin. Lymphoma Myeloma Leuk.
13
,
333
337
165
van Rhee
,
F.
,
Fayad
,
L.
,
Voorhees
,
P.
,
Furman
,
R.
,
Lonial
,
S.
,
Borghaei
,
H.
et al. 
(
2010
)
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease
.
J. Clin. Oncol.
28
,
3701
3708
166
Fizazi
,
K.
,
De Bono
,
J.S.
,
Flechon
,
A.
,
Heidenreich
,
A.
,
Voog
,
E.
,
Davis
,
N.B.
et al. 
(
2012
)
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
.
Eur. J. Cancer.
48
,
85
93
167
Rossi
,
J.-F.
,
Négrier
,
S.
,
James
,
N.D.
,
Kocak
,
I.
,
Hawkins
,
R.
,
Davis
,
H.
et al. 
(
2010
)
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
.
Br. J. Cancer
103
,
1154
1162
168
van Rhee
,
F.
,
Wong
,
R.S.
,
Munshi
,
N.
,
Rossi
,
J.-F.
,
Ke
,
X.-Y.
,
Fosså
,
A.
et al. 
(
2014
)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
.
Lancet Oncol.
15
,
966
974
169
Deisseroth
,
A.
,
Ko
,
C.-W.
,
Nie
,
L.
,
Zirkelbach
,
J.F.
,
Zhao
,
L.
,
Bullock
,
J.
et al. 
(
2015
)
FDA approval: siltuximab for the treatment of patients with multicentric castleman disease
.
Clin. Cancer Res.
21
,
950
954
170
German Clinical Trials Register. A multi-centre, exploratory trial to assess the mechanisms of molecular activity, safety and tolerability of one dose level of FE 999301 by intravenous infusions in patients with active inflammatory Bowel disease (IBD) [cited 17 Oct 2018]
171
US National Library of Medicine. ClinicalTrials.gov. Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis — Full Text View — ClinicalTrials.gov [cited 17 Oct 2018]
172
Sato
,
K.
,
Tsuchiya
,
M.
,
Saldanha
,
J.
,
Koishihara
,
Y.
,
Ohsugi
,
Y.
,
Kishimoto
,
T.
et al. 
(
1993
)
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth
.
Cancer Res.
53
,
851
856
PMID:
[PubMed]
173
Mihara
,
M.
,
Kasutani
,
K.
,
Okazaki
,
M.
,
Nakamura
,
A.
,
Kawai
,
S.
,
Sugimoto
,
M.
et al. 
(
2005
)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
.
Int. Immunopharmacol.
5
,
1731
1740
174
Nishimoto
,
N.
,
Sasai
,
M.
,
Shima
,
Y.
,
Nakagawa
,
M.
,
Matsumoto
,
T.
,
Shirai
,
T.
et al. 
(
2000
)
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
.
Blood
95
,
56
61
PMID:
[PubMed]
175
Nishimoto
,
N.
,
Yoshizaki
,
K.
,
Miyasaka
,
N.
,
Yamamoto
,
K.
,
Kawai
,
S.
,
Takeuchi
,
T.
et al. 
(
2004
)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
.
Arthritis Rheum.
50
,
1761
1769
176
Dhillon
,
S.
(
2014
)
Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis
.
BioDrugs
28
,
75
106
177
Le
,
R.Q.
,
Li
,
L.
,
Yuan
,
W.
,
Shord
,
S.S.
,
Nie
,
L.
,
Habtemariam
,
B.A.
et al. 
(
2018
)
FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome
.
Oncologist
23
,
943
947
178
van der Stegen
,
S.J.C.
,
Davies
,
D.M.
,
Wilkie
,
S.
,
Foster
,
J.
,
Sosabowski
,
J.K.
,
Burnet
,
J.
et al. 
(
2013
)
Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?
J. Immunol.
191
,
4589
4598
179
Norelli
,
M.
,
Camisa
,
B.
,
Barbiera
,
G.
,
Falcone
,
L.
,
Purevdorj
,
A.
,
Genua
,
M.
et al. 
(
2018
)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
.
Nat. Med.
24
,
739
748
180
Giavridis
,
T.
,
van der Stegen
,
S.J.C.
,
Eyquem
,
J.
,
Hamieh
,
M.
,
Piersigilli
,
A.
and
Sadelain
,
M.
(
2018
)
CAR t cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
.
Nat. Med.
24
,
731
738
181
Commissioner O of the. Press Announcements — FDA approves new treatment for moderately to severely active ulcerative colitis. Office of the Commissioner [cited 17 Oct 2018]
182
Garbers
,
C.
,
Heink
,
S.
,
Korn
,
T.
and
Rose-John
,
S.
(
2018
)
Interleukin-6: designing specific therapeutics for a complex cytokine
.
Nat. Rev. Drug Discov.
17
,
395
412
183
Liu
,
H.
,
Shen
,
J.
and
Lu
,
K.
(
2017
)
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
.
Biochem. Biophys. Res. Commun.
486
,
239
244
184
Mace
,
T.A.
,
Shakya
,
R.
,
Pitarresi
,
J.R.
,
Swanson
,
B.
,
McQuinn
,
C.W.
,
Loftus
,
S.
et al. 
(
2018
)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
.
Gut
67
,
320
332